丨证券研究报告丨 行业研究丨专题报告丨医疗保健 [Table_Title] 创新链系列——中国创新药研发投入景气度指 标 11 月跟踪 报告要点 [Table_Summary] 伴随着创新药企业 A/H 上市和增发充沛资金，二级市场创新药估值重塑和一级退出通道打通带 来中国生物医药投融资生态逐渐走向正循环，创新药对外 BD 涌现为研发投入注入新的资金来 源并拉动行业整体研发投入意愿，中国创新药研发投入景气度或渐趋改善，随之带来创新药产 业链进入新一轮景气周期。 分析师及联系人 [Table_Author] 彭英骐 万梦蝶 SAC：S0490524030005 SAC：S0490525050001 SFC：BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 医疗保健 cjzqdt11111 [Table_Title 创新链系列2] ——中国创新药研发投入景气度指 标 11 月跟踪 [Table_Summary2] 创新药上市通道变宽，IPO 募集资金充沛研发投入 创新药企业港股 IPO 热潮重现且在持续升温，未盈利企业科创板上市通道打开，创新药上市通 道 ...

Group 1 - The core viewpoint of the news highlights the ongoing volatility in the innovative drug sector, with a mixed performance among individual stocks, while some companies like Kangzhe Pharmaceutical and Green Leaf Pharmaceutical show resilience with over 1% gains [1] - The recent release of the "dual directory" for medical insurance and commercial insurance includes 114 new drugs for the national medical insurance drug list by 2025, with 50 being class 1 innovative drugs, indicating a sustained bullish trend for innovative drugs [3] - CITIC Construction Investment Securities notes that China's pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, with innovative drugs expected to be a major upward trend into 2026 [3] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has over 70% of its portfolio invested in leading innovative drug stocks, reflecting strong buying sentiment despite a slight decline in its market price [1][3] - The top ten holdings of the ETF account for 72.57% of its total weight, showcasing the dominance of leading companies in the innovative drug sector [3] - The ETF has a total market value of HKD 12.873 billion, with a daily average trading volume of HKD 4.58 billion since its inception, making it the largest and most liquid ETF tracking the same index [3]

Group 1 - The A-share market has shown a continuous volume contraction rebound, with improved funding conditions due to the warming expectations of the Federal Reserve's interest rate cuts and enhanced effectiveness of domestic fundamental pricing [1] - Recent improvements in the TMT and upstream resource sectors have been notable, with a focus on AI chains, pricing chains, capital goods, consumer goods, and infrastructure chains [1] - The upcoming "spring restlessness" in mid to late December may lead to an early start, balancing growth and cyclical investments, with a mid-term view favoring large financials and certain high-value consumer stocks as core choices for asset revaluation in China [1] Group 2 - The market is experiencing a rotation of volatility and structural opportunities, with traditional manufacturing and resource sectors being undervalued in terms of global pricing power [3] - Since the "9.24 market" last year, the overall market has seen a systematic increase in financing, with a net increase of 1.11 trillion yuan, significantly surpassing the total issuance of public and private bullish products since October of the previous year [3] - Major broad-based indices and thriving sectors have achieved most of their gains during these two market waves, while other periods have been relatively flat, with effective gains seen in quant-driven micro-accounts, insurance-driven banks, and price-driven non-ferrous metals [3] Group 3 - The market remains in an upward trend supported by funding and policy, with expectations for the A-share market to continue its bull run next year, supported by valuation and profit stabilization [4] - Easing geopolitical risks and renewed expectations of Federal Reserve interest rate cuts are likely to bring a pre-spring restlessness rally to the A-share market, with upcoming U.S.-China policy expectations being a key factor [4] - The AI sector is expected to continue its momentum under the 2026 U.S.-China interest rate cycle and strengthening AI trends, with a focus on "scarcity" in energy and power, as well as dual development in AI applications and ecosystem construction [4]

Investment Rating - The report maintains an investment rating of "Positive" for the pharmaceutical and biotechnology industry [2]. Core Viewpoints - The recent release of the "Medical Insurance + Commercial Insurance Dual Directory" by the National Medical Insurance Administration is expected to boost investment enthusiasm for innovative drugs. The report suggests focusing on investment opportunities in innovative drugs, CXO, and the upstream life sciences industry chain [3][9]. - The pharmaceutical sector is currently experiencing a lack of clear market direction, with the pharmaceutical commercial sector leading in performance. Notable stocks include Haiwang Biological (up 55.59%), Ruikang Pharmaceutical (up 36.54%), and Yue Wannianqing (up 15.37%) [3][9]. - The report emphasizes the importance of companies with stable dividends and operational improvements, as well as potential turning points in high-end medical devices [3][11]. Summary by Sections 1. Market Performance - The pharmaceutical and biotechnology sector's return was -0.74% last week, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices. The pharmaceutical commercial sector had the highest weekly return at 5.19% [3][7]. - Over the past month, the sector's return was -2.35%, also ranking 20th among sub-industry indices, with the pharmaceutical commercial sector leading at 5.78% [3][7]. 2. Innovative Drugs - The report recommends focusing on companies with leading product pipelines and market potential, including Innovent Biologics, 3SBio, Hengrui Medicine, and others [3][9][10]. 3. CXO and Upstream Life Sciences - Key CXO companies to watch include WuXi AppTec, WuXi Biologics, and others. The report also highlights clinical CRO leaders and resource-based CXOs [10]. 4. High-End Medical Devices - The report identifies several companies in the high-end medical device sector that may benefit from market recovery and increased demand, including Mindray Medical and others [11]. 5. Valuation Metrics - The current PE (TTM) for the pharmaceutical and biotechnology industry is 29.27 times, which is below the historical average of 30.88 times over the past five years [12][15].

Group 1 - The ChiNext 50 index is expected to have high elasticity under the profit growth forecast for 2026, driven by strong growth factors [1] - The index primarily covers sectors such as semiconductors, innovative pharmaceuticals, new energy, AI, humanoid robots, and high-end equipment, which are expected to benefit from valuation expansion during the 14th Five-Year Plan period [1] - The ChiNext 50 exhibits high gross margins (28.9% gross margin in H1 2025) and high free cash flow, aligning with the "quality large-cap growth" style [1] Group 2 - Short-term focus should be on North American AI capital expenditures supporting the technology industry chain, while mid-term observations should consider the long-term impact of AI productivity improvements on industry structure [1] - In the context of re-inflation, the technology manufacturing sector represented by the ChiNext 50 is expected to become a fundamental part of the market [1] - The Guotai ChiNext 50 ETF (159375) tracks the ChiNext 50 index (399673), which has a daily fluctuation limit of 20%, selecting 50 securities with good liquidity and large market capitalization from the ChiNext market [1]

Group 1 - The core viewpoint of the article highlights the ongoing volatility in the innovative pharmaceutical sector, with a mixed performance among individual stocks, while some, like Kangzhe Pharmaceutical and Green Leaf Pharmaceutical, have seen gains of over 1% [1][7] - The Hong Kong Stock Connect Innovative Pharmaceutical ETF (520880) has over 70% of its holdings in leading innovative pharmaceutical stocks, despite a current price drop of 1.08%, indicating strong buying interest as evidenced by a premium rate exceeding 0.5% [1][7] - The recent release of the dual directory for medical insurance and commercial insurance on December 7, 2023, includes 114 new drugs in the national medical insurance drug list for 2025, with 50 classified as Class 1 innovative drugs and 19 entering the commercial insurance innovative drug directory [1][8] Group 2 - Analysts suggest that the innovative pharmaceutical market is expected to continue its upward trend, remaining a key focus within the pharmaceutical sector, with significant investment safety margins and return potential [3][9] - CITIC Securities indicates that the Chinese pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [3][9] - The Hong Kong Stock Connect Innovative Pharmaceutical ETF (520880) is recommended as a primary investment vehicle, with its underlying index, the Hang Seng Hong Kong Stock Connect Innovative Pharmaceutical Select Index, showcasing three unique advantages: comprehensive coverage of innovative drug companies, significant weight in leading firms, and better risk control through reduced weight on less liquid stocks [9][10] Group 3 - As of November 30, 2023, the Hong Kong Stock Connect Innovative Pharmaceutical ETF has a scale of 2.142 billion yuan, with an average daily trading volume of 458 million yuan, making it the largest and most liquid ETF tracking the same index [5][10] - The top ten constituent stocks of the ETF account for 72.57% of its total weight, highlighting the dominance of leading innovative pharmaceutical companies [10] - The ETF's structure is designed to exclude CXO companies, focusing solely on pure innovative drug firms, thereby enhancing its appeal to investors seeking exposure to this sector [4][9]

Group 1 - CITIC Securities reports that a turning point in inventory has been observed since mid-November, with expectations for LME copper prices to accelerate towards $12,000 per ton by the end of the year due to interest rate cuts and domestic production reductions [1] - The report anticipates that the dual narrative of "U.S. copper hoarding" and "domestic production cuts" will resonate, potentially widening the supply gap by 60%, establishing $12,000 as a new starting point for copper prices [1] - A comprehensive recommendation for allocation in the copper sector is provided [1] Group 2 - Cinda Securities indicates that the foundation for a bull market remains solid, with the recent market volume contraction attributed to the digestion of high turnover rates and trading congestion in certain sectors, both of which have eased [2] - The report suggests that low trading volumes during a bull market are not a negative signal, as historical patterns show that volume lows often coincide with market bottoms [2] - The period around December 2025 is highlighted as a potential window for positioning ahead of a year-end market rally [2] Group 3 - Huaxi Securities expects an influx of new capital into the A-share market as the year ends, driven by anticipated interest rate cuts from the Federal Reserve and a strong RMB supporting foreign investment in Chinese assets [3] - The report notes that the recent low trading volume and declining implied volatility in options indicate that the market is awaiting new guiding themes [3] - Recommended sectors for investment include high-growth areas supported by industrial policy, such as innovative pharmaceuticals and AI applications, as well as non-ferrous metals benefiting from improved overseas liquidity [3]

Core Viewpoint - The report by Shenwan Hongyuan outlines ten key investment opportunities during the "14th Five-Year Plan" period, focusing on future manufacturing, information, materials, energy, space, and health sectors [1][14]. Group 1: Future Manufacturing and Information - The robotics industry in China is transitioning from product definition to commercialization, with "Artificial Intelligence +" expected to empower various industries by 2026 [3][16]. - Quantum technology is highlighted as a critical future industry for forward-looking development [3][16]. Group 2: Aerospace and Low-altitude Economy - The aerospace industry is a key focus for the "14th Five-Year Plan," with the establishment of the Space Administration and a three-year action plan to promote high-quality and safe development in commercial aerospace [3][16]. - The drone and low-altitude economy sectors are rapidly forming a clustered development pattern [3][16]. Group 3: Strategic Resources and Metals - Strategic minor metals are receiving policy support, with a joint work plan from eight departments elevating resource security to a strategic level [7][20]. - A table outlines various metals and their applications across different industries, emphasizing their importance in sectors like defense, aerospace, and renewable energy [8][21]. Group 4: Future Energy - The development of controllable nuclear fusion is emphasized as a priority, with significant energy demand driving investments in nuclear power from major companies [9][22]. - The report notes the strategic cultivation of hydrogen energy within the future industrial framework [9][22]. Group 5: Future Health - China's innovative drug development has established global competitiveness in areas like ADC and cell therapy, achieving breakthroughs in both the quantity and quality of research pipelines [11][24]. - Brain-computer interface technology is advancing in clinical applications, with significant progress in medical rehabilitation as a primary commercialization scenario [13][26].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 随着"十五五"规划蓝图绘就，中国资本市场高质量发展的路线图进一步清晰。证监会主席吴清日前指 出，未来五年是全面深化资本市场改革、加快打造一流投行和投资机构的战略机遇期。政策信号明确之 下，多家头部券商密集发布展望报告，拆解规划带来的投资新范式。 聚焦金融行业自身的改革与成长机遇 中信证券研究表示，"十五五"期间，证券行业格局有望深度重塑，推动行业实现错位发展，10家引领行 业发展的综合性机构将逐步成型。投行业务、衍生品业务、期货业务和资产证券化业务的监管周期有望 逐步回暖，证券公司有望通过内生增长和并购重组实现自身的长足发展，资产配置、综合服务和国际化 能力有望成为行业分化的决定因素。建议关注冲击国际一流投行的龙头证券公司以及具备跻身头部梯队 潜力的中大型证券公司。 国泰海通金融团队指出，保险业、券商业、银行业在 "十五五" 期间的发展目标与预期明确，将实现规 模与质量协同提升。1）保险业预计规模与质量双升，2030 年保费收入或达 8 万亿元、行业总资产有望 突破 60 万亿元，更加突出保险服务实体经济的 "减震器" 与保障民生的 " ...

Group 1 - The private equity industry in China experienced a surge in new product registrations in November, with 1,285 products registered, marking a nearly 30% month-on-month increase and the second-highest monthly record of the year [1] - The stock private equity position index reached 82.97% as of November 21, 2025, a significant increase of 1.84% from the previous week, setting a new annual high and a 185-week record [2] - The number of stocks reaching historical highs increased to 57 in the week of December 1-5, 2025, showing a recovery trend despite a recent market pullback [4] Group 2 - The 2025 National Medical Insurance Drug List added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly up from 76% in 2024 [3] - The People's Bank of China has increased its gold reserves for the 13th consecutive month, with reserves reported at 7.412 million ounces as of the end of November [5] - A new satellite manufacturing facility in Wenchang International Space City is set to produce 1,000 satellites annually, enhancing the satellite production ecosystem in China [6] Group 3 - This week, five new stocks are set to be issued, including one from the Shanghai main board, one from the Sci-Tech Innovation Board, one from the Shenzhen main board, and two from the Growth Enterprise Market [7] - Nearly 400 billion yuan worth of locked shares will be unlocked this week, with ten companies having over 1 billion yuan in locked share value [9] - The upcoming Federal Reserve meeting on December 9-10 is expected to result in a 25 basis point cut in policy rates [10]